Tumor Biology

, Volume 36, Issue 1, pp 329–335 | Cite as

RETRACTED ARTICLE: The effect of CCL19/CCR7 on the proliferation and migration of cell in prostate cancer

  • Cheng Peng
  • Keliang Zhou
  • Sensheng An
  • Jie Yang
Research Article


Multiple studies have shown that CC motif chemokine ligand 19 (CCL19) promotes cell proliferation in several human cancers. In this study, we investigated the clinical significance of CCL19 and its specific receptor CCR7 and its function in our large collection of prostate samples. Between August 2000 and December 2013, 108 patients with histologically confirmed prostate cancer (PCa) and 80 with benign prostate hyperplasia (BPH) were recruited into the study. Quantitative RT-PCR immunohistochemistry analyses were used to quantify CCL19 and CCR7 expression in PCa cell lines and clinical samples. The functional role of CCL19 in PCa cell lines was evaluated by small interfering RNA-mediated depletion of the protein followed by analyses of cell proliferation and invasion. The positive rate of CCL19 staining was 87.04 % (94/108) in 108 cases of prostatic carcinoma and 16.25 % (13/80) in 80 cases of BPH, and high expression of CCR7 was observed in 83.33 % (90/108) of the PCa tissues versus (17.50 %; 14/80) of the BPH tissues, the difference of CCL19 and CCR7 expression between two groups was statistically significant, respectively. The results were confirmed by quantitative real-time PCR. CCL19 and CCR7 were significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells. Silencing of CCL19 inhibited the proliferation of DU-145 cells which have a relatively high level of CCL19 in a time- and concentration-dependent manner, and the invasion and migration of DU-145 cells were distinctly suppressed. Our data suggest that the pathogenesis of human PCa maybe mediated by the CCL19/CCR7 axis, and CCL19 inhibition treatment may provide a promising strategy for the anti-tumor therapy of PCa.


Prostate cancer Chemokines Chemokine receptors CCL19 CCR7 Proliferation Migration Targeted therapy 


Conflicts of interest



  1. 1.
    Ren SC, Chen R, Sun YH. Prostate cancer research in China. Asian J Androl. 2013;15:350–3.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Saad F, Pantel K. The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. Future Oncol. 2012;8:321–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011;59(1):61–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol. 2010;22:263–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang T, Liu Z, Guo S, Wu L, Li M, Yang J, et al. The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer. Oncotarget. 2014;5(11):3611–21.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Roussos ET, Condeelis JS, Patsialou A. Chemotaxis in cancer. Nat Rev Cancer. 2011;11:573–87.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH, Sun J, et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Res. 2012;72(14):3546–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Maxwell PJ, Neisen J, Messenger J, Waugh DJ. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells. Oncotarget. 2014;5(13):4895–908.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Qin L, Gong C, Chen AM, Guo FJ, Xu F, Ren Y, et al. Peroxisome proliferator-activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Mol Med Rep. 2014;10(2):695–700.PubMedGoogle Scholar
  10. 10.
    Cao M, Deng HX, Zhao J, Fan LY, Jiang Y, Wen YJ, et al. Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene. Biotechnol Appl Biochem. 2007;48(2):109–16.CrossRefPubMedGoogle Scholar
  11. 11.
    Lu J, Zhao J, Feng H, Wang P, Zhang Z, Zong Y, et al. Antitumor efficacy of CC motif chemokine ligand 19 in colorectal cancer. Dig Dis Sci. 2014 Apr 5. [Epub ahead of print]Google Scholar
  12. 12.
    Oliveira-Neto HH, de Souza PP, da Silva MR, Mendonça EF, Silva TA, Batista AC. The expression of chemokines CCL19, CCL21 and their receptor CCR7 in oral squamous cell carcinoma and its relevance to cervical lymph node metastasis. Tumour Biol. 2013;34(1):65–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Johrer K, Pleyer L, Olivier A, Maizner E, Zelle-Rieser C, Greil R. Tumour-immune cell interactions modulated by chemokines. Expert Opin Biol Ther. 2008;8:269–90.CrossRefPubMedGoogle Scholar
  14. 14.
    Hamanishi J, Mandai M, Matsumura N, et al. Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells. 2010;28:164–73.PubMedGoogle Scholar
  15. 15.
    Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunol. 2013;2(9):e26245.CrossRefGoogle Scholar
  16. 16.
    Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16:664–73.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Cheng Peng
    • 1
  • Keliang Zhou
    • 1
  • Sensheng An
    • 1
  • Jie Yang
    • 1
  1. 1.Department of Urology456 Hospital of PLAJinanChina

Personalised recommendations